Lin Chih-Chieh, Kuo Hann-Chorng, Li Jian-Ri, Chuang Yao-Chi
Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan.
School of Medicine, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Int Neurourol J. 2023 Sep;27(3):182-191. doi: 10.5213/inj.2346148.074. Epub 2023 Sep 30.
We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus cavernosum relaxation.
In this 4-site, randomized controlled trial, 150 sexually active men with OAB were enrolled between June 2020 and May 2022. Participants were randomly allocated (1:2) into 2 treatment groups: (1) behavioral therapy alone (n = 50) and (2) a combination of mirabegron 50 mg daily and behavioral therapy (n = 100). The evaluation was based on the overactive bladder symptoms score (OABSS), the International Index of Erectile Function, the ejaculatory domain short form, the International Prostate Symptom Score, patient perception of bladder condition, quality of life, and urodynamic parameters. The therapeutic outcomes were assessed at baseline, 4 weeks, and 12 weeks.
There were 65 patients (65%) in the combination subgroup and 36 patients in the behavioral therapy who completed all 12 weeks of treatment. Both groups had a statistically significant improvement in OABSS after 12 weeks of treatment. The combination therapy group achieved a statistically significant improvement in all 4 subscores of OABSS, however, the urinary frequency (P = 0.120) and urinary incontinence (P = 0.234) subscores in the behavioral therapy only group did not show a significant change. Additionally, the combination group had a significant improvement in functional bladder capacity, which was not seen in the behavioral therapy group. However, both groups did not have a significant change in erectile or ejaculatory function.
Behavioral therapy combined with mirabegron had more significant impact on the improvement of OAB than behavior therapy alone. However, both groups did not have significant changes in erectile or ejaculatory function.
我们评估了行为疗法联合或不联合米拉贝隆对性活跃的膀胱过度活动症(OAB)男性患者OAB症状和性功能的治疗效果。米拉贝隆是一种用于治疗OAB的选择性β3肾上腺素能受体激动剂,已被证明可诱导海绵体松弛。
在这项4中心随机对照试验中,2020年6月至2022年5月期间招募了150名性活跃的OAB男性患者。参与者被随机(1:2)分配到2个治疗组:(1)单纯行为疗法组(n = 50)和(2)每日50 mg米拉贝隆联合行为疗法组(n = 100)。评估基于膀胱过度活动症症状评分(OABSS)、国际勃起功能指数、射精领域简表、国际前列腺症状评分、患者对膀胱状况的感知、生活质量和尿动力学参数。在基线、4周和12周时评估治疗结果。
联合治疗亚组中有65例患者(65%)完成了全部12周的治疗,行为疗法组有36例患者完成治疗。两组在治疗12周后OABSS均有统计学显著改善。联合治疗组在OABSS的所有4个子评分上均取得了统计学显著改善,然而,单纯行为疗法组的尿频(P = 0.120)和尿失禁(P = 0.234)子评分未显示出显著变化。此外,联合治疗组的功能性膀胱容量有显著改善,而行为疗法组未观察到这一变化。然而,两组的勃起或射精功能均无显著变化。
与单纯行为疗法相比,行为疗法联合米拉贝隆对改善OAB有更显著的影响。然而,两组的勃起或射精功能均无显著变化。